Acadia Pharmaceuticals (ACAD) Fundamental Analysis: Revenue, Earnings & Valuation

1.82 / 10

Underperform

Fundamental assessment scores 1.8/10, earning an Underperform rating. Profit‑MV and Cash‑MV are strengths, while Revenue‑MV, Asset‑MV, gross margin and tax ratios are weak, indicating constrained earnings and asset efficiency despite decent inventory and fixed‑asset turnover.

Analysis Checks(6/10)

Revenue-MV

Value-0.58

Score1/3

Weight20.90%

1M Return5.44%

Inventory turnover ratio

Value3.14

Score2/3

Weight-1.54%

1M Return-0.56%

Gross profit margin (%)

Value91.69

Score0/3

Weight-12.16%

1M Return-5.42%

Profit-MV

Value1.40

Score2/3

Weight23.86%

1M Return6.36%

Income tax / Total profit (%)

Value-181.49

Score3/3

Weight8.39%

1M Return2.26%

Current assets turnover ratio

Value1.07

Score1/3

Weight-0.52%

1M Return-0.17%

Fixed assets turnover ratio

Value20.28

Score2/3

Weight0.03%

1M Return0.01%

Cost of sales ratio (%)

Value8.31

Score2/3

Weight-9.78%

1M Return-3.62%

Asset-MV

Value-0.55

Score1/3

Weight47.45%

1M Return11.48%

Cash-MV

Value0.03

Score2/3

Weight23.37%

1M Return6.19%

Is ACAD undervalued or overvalued?

ACAD scores 1.82/10 on fundamentals and holds a Premium valuation at present. Backed by its 39.89% ROE, 36.49% net margin, 9.05 P/E ratio, 2.88 P/B ratio, and 69.34% earnings growth, these metrics solidify its Underperform investment rating.